Sunesis Pharmaceuticals to Present Data on SNS-595 and Kinase Inhibitor Programs at the Upcoming AACR-NCI-EORTC International Conference
SOUTH SAN FRANCISCO, Calif., Nov 07, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will present scientific and clinical updates through two poster sessions and one oral presentation at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference at the Philadelphia Convention Center in Philadelphia, PA, November 14-18, 2005.
-- Sunesis will present the results of a 41 patient Phase I clinical trial of SNS-595, the company's lead novel cancer therapeutic, through a poster titled "Results of a Phase I Trial of SNS-595 in Patients with Advanced Solid Malignancies," at Poster Session B on Wednesday, November 16. -- The company will also present data on SNS-595's mechanism of action through a poster titled "CYP450 Inhibition, Induction, Metabolism and Routes of Elimination of SNS-595, a Novel Cell Cycle Inhibitor Currently in Phase I Clinical Trials," at Poster Session C on Thursday, November 17. -- Robert McDowell, Ph.D., VP of Chemistry at Sunesis will present a talk entitled "Discovery of Novel Modular Kinase Inhibitors," at the Structural Approaches to Drug Discovery session on Thursday, November 17. About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com .
This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.
SOURCE Sunesis Pharmaceuticals, Inc.
investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc., +1-650-266-3717; or media, Karen L. Bergman or Michelle Corral, +1-650-575-1509 or +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals, Inc.
Copyright (C) 2005 PR Newswire. All rights reserved.
News Provided by COMTEX